Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, that develops therapies for serious, rare genetic skin diseases for which there are no approved treatments. Its shares trade on Nasdaq under the ticker PVLA; the company became public in late 2024 through a merger with Pieris Pharmaceuticals.

Palvella's work is built on its QTORIN platform, which is designed to deliver drugs directly into the skin to achieve high local concentrations while limiting exposure in the rest of the body. The lead product candidate, QTORIN rapamycin, is a topical anhydrous gel formulation of the mTOR inhibitor rapamycin.

The company is developing QTORIN rapamycin for microcystic lymphatic malformations and cutaneous venous malformations, conditions driven by overactive mTOR signaling, and is evaluating the platform for additional rare dermatological disorders.